CG Oncology develops Cretostimogene, an intravesically delivered oncolytic immunotherapy for non‑muscle invasive bladder cancer (NMIBC). The therapy uses a genetically engineered virus to directly lyse tumor cells and stimulate a systemic immune response, aiming to reduce recurrence and preserve the bladder. It is being evaluated in a comprehensive clinical program for safety and efficacy, targeting urologists, oncologists, and healthcare systems seeking bladder‑sparing treatments.
Funding
$238M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with non‑muscle invasive bladder cancer (NMIBC) often require repeated intravesical therapies or surgical interventions, which can be invasive, carry significant side effects, and have high recurrence rates.
Solution
CG Oncology is developing Cretostimogene, an intravesically administered oncolytic immunotherapy designed to treat NMIBC while preserving the bladder. The therapy combines direct oncolysis of tumor cells with stimulation of a systemic anti‑tumor immune response, aiming to reduce recurrence and delay or avoid more invasive procedures. It is being evaluated in a comprehensive clinical development program to establish safety and efficacy for bladder‑sparing treatment.
Target Audience
Primary customers are urologists and oncologists treating patients with NMIBC, as well as healthcare systems seeking bladder‑sparing therapeutic options.
Features
- Intravesical delivery of a genetically engineered oncolytic virus targeting bladder tumor cells
- Dual mechanism: direct tumor cell lysis plus activation of host immune response
- Formulated for repeated administration without the need for surgical implantation
- Designed specifically for non‑muscle invasive bladder cancer indications
- Supported by an extensive clinical trial program assessing safety, tolerability, and efficacy